Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 1/20 | 0.61 |
| ▸ | CASP3 | P42574 | 3/20 | 0.47 |
| ▸ | SENP7 | Q9BQF6 | 3/20 | 0.47 |
| ▸ | SENP8 | Q96LD8 | 2/20 | 0.47 |
| ▸ | SENP6 | Q9GZR1 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 3/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | CCR2 | P41597 | 1/20 | 0.38 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24322069 | 0.85 | DAO (0.63) | DAOCASP3SENP7SENP8SENP6 | |
| SCHEMBL5436576 | 0.82 | ALDH1A1 (0.63) | DAOCASP3SENP7SENP8SENP6 | |
| SCHEMBL15296865 | 0.81 | DAO (0.49) | DAOCASP3SENP7SENP8SENP6 | |
| SCHEMBL16520935 | 0.79 | DAO (0.47) | DAOCASP3SENP7SENP8SENP6 | |
| SCHEMBL24425982 | 0.79 | ALDH1A1 (0.66) | ALDH1A1LMNAMAPTKDM4EHPGD | |
| SCHEMBL161466 | 0.79 | ALDH1A1 (0.41) | DAOALDH1A1LMNAMAPTKDM4E | |
| SCHEMBL13631431 | 0.79 | DAO (0.55) | DAOCASP3SENP7SENP8SENP6 | |
| SCHEMBL10274827 | 0.79 | DAO (0.55) | DAOCASP3SENP7SENP8SENP6 | |
| SCHEMBL19961112 | 0.78 | DAO (0.46) | DAOCASP3SENP7SENP8SENP6 | |
| SCHEMBL7368425 | 0.78 | DAO (0.71) | DAOCASP3SENP7SENP8SENP6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12552757-B2 | NRF2-activating compound | SENJU PHARMACEUTICAL CO., LTD. (JP) | 2026-02-17 | — | — | US | disclosed |
| US-20240132519-A1 | NRF2-ACTIVATING COMPOUND | SENJU PHARMACEUTICAL CO., LTD. (JP) | 2024-04-25 | — | — | US | disclosed |
| WO-2024057020-A1 | ANTI-VIRAL COMPOUNDS | Infex Therapeutics Limited (GB) | 2024-03-21 | — | — | WO | disclosed |
| CN-112409331-B | Heterocyclic derivative inhibitor, preparation method and application thereof | 上海翰森生物医药科技有限公司 | 2024-02-20 | — | — | CN | disclosed |
| WO-2023223055-A1 | ANTI-VIRAL COMPOUNDS | Infex Therapeutics Limited (GB) | 2023-11-23 | — | — | WO | disclosed |
| EP-4273145-A1 | NRF2-ACTIVATING COMPOUND | Senju Pharmaceutical Co., Ltd. (JP) | 2023-11-08 | — | — | EP | disclosed |
| EP-4273145-A1 | NRF2-ACTIVATING COMPOUND | Senju Pharmaceutical Co., Ltd. (JP) | 2023-11-08 | — | — | EP | disclosed |
| CN-116669744-A | Nrf2 activating compounds | 千寿制药株式会社 | 2023-08-29 | — | — | CN | disclosed |
| US-20230024995-A1 | NRF2-ACTIVATING COMPOUND | SENJU PHARMACEUTICAL CO., LTD. (JP) | 2023-01-26 | — | — | US | disclosed |
| US-20230024995-A1 | NRF2-ACTIVATING COMPOUND | SENJU PHARMACEUTICAL CO., LTD. (JP) | 2023-01-26 | — | — | US | disclosed |
| EP-2287162-A1 | Derivatives of 4-piperazin-1-yl-4-benzo[b]thiophene suitable for the treatment of cns disorders | Otsuka Pharmaceutical Co., Ltd. (JP) | 2011-02-23 | — | — | EP | disclosed |
| EP-2287161-A1 | Derivatives of 4-piperazin-1-yl-4-benzo[b]thiophene suitable for the treatment of cns disorders | Otsuka Pharmaceutical Co., Limited (JP) | 2011-02-23 | — | — | EP | disclosed |
| EP-2284169-A1 | Derivatives of 4-piperazin-1-yl-4-benzo[b]thiophene suitable for the treatment of CNS disorders | Otsuka Pharmaceutical Co., Limited (JP) | 2011-02-16 | — | — | EP | disclosed |
| US-7622464-B2 | Morpholinyl-urea derivatives for use in the treatment of inflammatory diseases | GLAXO GROUP LIMITED (GB) | 2009-11-24 | — | — | US | disclosed |
| US-7622464-B2 | Morpholinyl-urea derivatives for use in the treatment of inflammatory diseases | GLAXO GROUP LIMITED (GB) | 2009-11-24 | — | — | US | disclosed |
| EP-1487828-B1 | MORPHOLINYL-UREA DERIVATIVES FOR USE OF THE TREATMENT OF INFLAMATORY DISEASES | GLAXO GROUP LTD (GB) | 2008-11-05 | — | — | EP | disclosed |
| US-20080221092-A1 | Heterobicyclic metalloprotease inhibitors | BLUHM HARALD | 2008-09-11 | — | — | US | disclosed |
| US-20080221083-A1 | Heterobicyclic metalloprotease inhibitors | HOCHGURTEL MATTHIAS | 2008-09-11 | — | — | US | disclosed |
| US-20080221092-A1 | Heterobicyclic metalloprotease inhibitors | BLUHM HARALD | 2008-09-11 | — | — | US | disclosed |
| WO-2007026959-A2 | DERIVATIVES OF 4-PIPERAZIN-1-YL-4-BENZ0 [B] THIOPHENE SUITABLE FOR THE TREATMENT OF CNS DISORDERS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230024995-A1 | NRF2-ACTIVATING COMPOUND | NFE2L2, KEAP1, NFE2 | DAO 3062/4885CASP3 3813/4885SENP7 4301/4885 |
| US-20080221083-A1 | Heterobicyclic metalloprotease inhibitors | MMP13, MMP3, TIMP3 | DAO 753/4885CASP3 161/4885SENP7 612/4885 |
| US-12552757-B2 | NRF2-activating compound | NFE2L2, NFE2, KEAP1 | DAO 2771/4885CASP3 2960/4885SENP7 3300/4885 |
| US-20240132519-A1 | NRF2-ACTIVATING COMPOUND | NFE2L2, KEAP1, NFE2 | DAO 2854/4885CASP3 1814/4885SENP7 3187/4885 |
| US-20080221092-A1 | Heterobicyclic metalloprotease inhibitors | MMP13, MMP3, TIMP3 | DAO 775/4885CASP3 155/4885SENP7 588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.